二次進行型多発性硬化症患者におけるオレラブルチニブの研究
非活動性二次進行型多発性硬化症患者におけるオレラブルチニブとプラセボの有効性および安全性を比較する第3相無作為化二重盲検試験
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
調査の概要
詳細な説明
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Patient and Medical Information
- 電話番号:833-269-4696
- メール:clinicaltrialsinfo@zenasbio.com
研究連絡先のバックアップ
- 名前:Patient and Medical Information
- 電話番号:833-269-4696
- メール:clinialtrialsinfo@zenasbio.com
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85032
- 募集
- Arizona Neuroscience Research, LLC
-
Scottsdale、Arizona、アメリカ、85253
- 募集
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton、California、アメリカ、92835
- 募集
- Fullerton Neurology and Headache Center
-
Torrance、California、アメリカ、90502-2006
- 募集
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood、California、アメリカ、90048
- 募集
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton、Florida、アメリカ、33487
- 募集
- SFM Clinical Research, LLC
-
Bradenton、Florida、アメリカ、34209
- 募集
- Nova Clinical Research, LLC
-
Clearwater、Florida、アメリカ、33761
- 募集
- MS and Neuromuscular Center of Excellence
-
Maitland、Florida、アメリカ、32751
- 募集
- Neurology Associates
-
Naples、Florida、アメリカ、34105
- 募集
- Aqualane Clinical Research
-
Tampa、Florida、アメリカ、33612
- 募集
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46256
- 募集
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Medical Center
-
Roeland Park、Kansas、アメリカ、66205
- 募集
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02131
- 引きこもった
- Boston Clinical Trials
-
Worcester、Massachusetts、アメリカ、01655
- 募集
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills、Michigan、アメリカ、48307
- 募集
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87131
- 募集
- University Of New Mexico School Of Medicine
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43235
- 募集
- The Boster Center for Multiple Sclerosis
-
Columbus、Ohio、アメリカ、43221
- 募集
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29605
- 募集
- Premier Neurology
-
-
Tennessee
-
Cordova、Tennessee、アメリカ、38018
- 募集
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio、Texas、アメリカ、78258
- 募集
- Lone Star Neurology
-
Sherman、Texas、アメリカ、75092
- 募集
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
Chieti
-
Chieti、Chieti、イタリア、66100
- 募集
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli、Isernia/Molise、イタリア、86077
- 募集
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
-
Vinnytsia、ウクライナ、21009
- 募集
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi、Chernivtsi Oblast、ウクライナ、58023
- 募集
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk、Ivano-Frankivs'k Oblast、ウクライナ、76018
- 募集
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv、Lviv Oblast、ウクライナ、79000
- 募集
- Limited Liability Company Medical Center Neuroclinic
-
Lviv、Lviv Oblast、ウクライナ、79029
- 募集
- Limited Liability Company "Neurofocus"
-
-
-
-
Harju
-
Tallinn、Harju、エストニア、10617
- 募集
- Astra clinic (Clinic4U)
-
-
-
-
New South Wales
-
Kogarah、New South Wales、オーストラリア、2217
- 募集
- Southern Neurology Suite 2
-
-
-
-
Athens
-
Cholargós、Athens、ギリシャ、15562
- 募集
- Metropolitan General Hospital
-
-
Attica
-
Athens、Attica、ギリシャ、11526
- 募集
- Errikos Dunant Hospital
-
-
-
-
-
Zagreb、クロアチア、10 000
- 募集
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
-
Tbilisi、グルジア、0114
- 募集
- LTD Pineo Medical Ecosystem
-
Tbilisi、グルジア、0186
- 募集
- Raymann, LLC
-
Tbilisi、グルジア、0159
- 募集
- NNLE Jo Ann University Hospital
-
Tbilisi、グルジア、0186
- 募集
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi、K'alak'i T'bilisi、グルジア、0114
- 募集
- JSC Curatio
-
-
Saburtalo
-
Tbilisi、Saburtalo、グルジア、0160
- 募集
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
A Coruña
-
A Coruña、A Coruña、スペイン、15006
- 募集
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo、Galicia、スペイン、36312
- 募集
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid、Madrid、スペイン、28007
- 募集
- Hospital Gregorio Marañon
-
Majadahonda、Madrid、スペイン、28222
- 募集
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga、Málaga、スペイン、29016
- 募集
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta、Seville、スペイン、41950
- 募集
- Hospital Vithas Nisa Sevilla
-
-
-
-
-
Kragujevac、セルビア、34000
- 募集
- University Clinical Centre of Kragujevac
-
Niš、セルビア、18000
- 募集
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade、Belgrade、セルビア、11000
- 募集
- University Clinical Centre of Serbia
-
-
-
-
-
Choceň、チェコ、56501
- 募集
- NEUROHK, s.r.o.
-
Jihlava、チェコ、58601
- 募集
- Regional Hospital Jihlava
-
-
-
-
Hesse
-
Bad Homburg、Hesse、ドイツ、61348
- 募集
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
-
Budapest、ハンガリー、1145
- 募集
- National Institute of Clinical Neurosciences
-
Tatabánya、ハンガリー、2800
- 募集
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom、Komarom-Esztergom Vamegye、ハンガリー、2500
- 募集
- Valeomed Kft.
-
-
-
-
Gard
-
Nîmes、Gard、フランス、30029
- 募集
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
-
-
-
Pleven、ブルガリア、5800
- 募集
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv、Plovdiv、ブルガリア、4000
- 募集
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia、Sofia、ブルガリア、1680
- 募集
- Diagnostic and Consultative Center Convex
-
Sofia、Sofia、ブルガリア、1510
- 募集
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo、Tarnovo、ブルガリア、5000
- 募集
- Medical Center Medica Plus OOD
-
-
-
-
-
Guaynabo、プエルトリコ、00969
- 募集
- Caribbean Center for Clinical Research
-
-
-
-
Limburg
-
Overpelt、Limburg、ベルギー、3900
- 募集
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Lublin、ポーランド、20-064
- 募集
- Galen Clinic
-
Poznan、ポーランド、15-540
- 募集
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin、ポーランド、70-111
- 募集
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory、ポーランド、44-240
- 募集
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、ポーランド、85-605
- 募集
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、ポーランド、20-601
- 募集
- Malva Trials
-
Lublin、Lublin Voivodeship、ポーランド、20-064
- 募集
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin、Lublin Voivodeship、ポーランド、20-064
- 募集
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól、Lubusz Voivodeship、ポーランド、67-100
- 募集
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw、Mazovian、ポーランド、02-172
- 募集
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów、Rzeszów、ポーランド、35-323
- 募集
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice、Silesian Voivodeship、ポーランド、40-081
- 募集
- Centrum Medyczne Pratia Katowice
-
Katowice、Silesian Voivodeship、ポーランド、40-571
- 募集
- MA-LEK Clinical Sp. z o.o.
-
Katowice、Silesian Voivodeship、ポーランド、40-584
- 募集
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice、Upper Silesia、ポーランド、40-686
- 募集
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan、Wielkopolska、ポーランド、61-853
- 募集
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan、Wielkopolska、ポーランド、60-324
- 募集
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、ポーランド、91-743
- 募集
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz、Łódź Voivodeship、ポーランド、90-324
- 募集
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
Kauno
-
Kaunas、Kauno、リトアニア、50161
- 募集
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
Constanța County
-
Constanța、Constanța County、ルーマニア、900123
- 募集
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti、Suceava、ルーマニア、725400
- 募集
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
プラセボコンパレーター:Placebo Group
Placebo PO daily |
Placebo orally |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
時間枠:Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
12 Week CDP
時間枠:Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
時間枠:Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
時間枠:Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
時間枠:Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
時間枠:Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
時間枠:Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
時間枠:Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
時間枠:Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
時間枠:Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
時間枠:Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ZB020-03-002
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。